Persistent Atrial Fibrillation Clinical Trial
— WATCH-RhythmOfficial title:
WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm
NCT number | NCT03835338 |
Other study ID # | S2236 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | September 1, 2021 |
Est. completion date | April 30, 2024 |
Verified date | March 2022 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
WATCH-Rhythm is a prospective, randomized, multi-center, investigation to collect safety and effectiveness data on combining conventional AF ablation with LAA electric isolation and closure within a single procedure.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 30, 2024 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. The subject is of legal age to participate in the study per the laws of their respective geography. 2. The subject has documented non-valvular persistent AF. For this protocol, the definition of persistent AF is sustained arrhythmia lasting at least 7-days but less than 36 months. 3. The subject is able to tolerate OAC post ablation. 4. Subject is able to undergo TEE. 5. The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial 6. The subject is willing and capable of attending all follow-up visits at the investigational site as medically appropriate. Exclusion Criteria: 1. The subject is unable or unwilling to return for required follow-up visits and examinations. 2. The subject had or is planning to have any invasive cardiac procedure within 30 days prior to randomization (e.g., cardioversion, ablation). 3. Previous AF ablation (surgical or percutaneous). 4. Prior MAZE procedure. 4. The subject is planning to have any cardiac or non-cardiac invasive or surgical procedure that would necessitate stopping or modifying the protocol required medication regimen within 90 days after the WATCHMAN Closure Device implant (e.g., cardioversion, ablation, cataract surgery). 5. The subject had a prior BARC type 3 or 4 bleeding event within the 14 days prior to randomization. Lack of resolution of related clinical sequelae, or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event. 6. The subject had a prior stroke (of any cause) or TIA within the 30 days prior to randomization. 7. The subject had a prior BARC type 3 or 4 bleeding event within the 14 days prior to randomization. Lack of resolution of related clinical sequelae, or planned and pending interventions to resolve bleeding/bleeding source, or a further exclusion regardless of timing of the bleeding event. 8. The subject has a history of atrial septal repair or has an ASD/PFO device. 9. The subject has an implanted mechanical valve prosthesis in any position. 10. The subject suffers from New York Heart Association Class IV Congestive Heart Failure. 11. Subject has LVEF <30% 12. Subject has hypertrophic cardiomyopathy. 13. The subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST elevation MI (STEMI), with or without intervention, within 90 days prior to randomization. 14. The subject is of childbearing potential and is, or plans to become pregnant during the time of the study (method of assessment upon study physician's discretion). 15. The subject is currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility. 16. The subject has a documented life expectancy of less than two years. 17. The subject has a known or suspected hypercoagulable state |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Freedom from AF | Not having any of the following after the blanking period:
a documented symptomatic AF event (episode of 30 sec duration or longer by Holter, event monitor or rhythm strip; or for the full 10 second recording of a standard 12 lead ECG) treatment with a Class I or Class III AAD a documented symptomatic AF event (episode of 30 sec duration or longer by Holter, event monitor or rhythm strip; or for the full 10 second recording of a standard 12 lead ECG) treatment with a Class I or Class III AAD |
12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT03650556 -
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
|
N/A | |
Recruiting |
NCT04085731 -
Driver-guided Ablation of Persistent Atrial Fibrillatiom
|
||
Withdrawn |
NCT02344394 -
Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation
|
N/A | |
Completed |
NCT01694563 -
ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
|
N/A | |
Terminated |
NCT01683045 -
Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats
|
N/A | |
Active, not recruiting |
NCT03643224 -
DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
|
N/A | |
Withdrawn |
NCT05093868 -
Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)
|
N/A | |
Completed |
NCT05152966 -
Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
|
N/A | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Active, not recruiting |
NCT06124690 -
Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas
|
N/A | |
Not yet recruiting |
NCT05454111 -
CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation
|
N/A | |
Completed |
NCT06260670 -
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT05077670 -
Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
|
||
Completed |
NCT02275104 -
Multimodal Image Processing Software to Guide Cardiac Ablation Therapy
|
N/A | |
Not yet recruiting |
NCT05565183 -
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
|
N/A | |
Completed |
NCT02274857 -
Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
|
N/A | |
Completed |
NCT01014741 -
Modified Ablation Guided by Ibutilide Use in Chronic Atrial Fibrillation
|
N/A |